OBJECTIVES: To investigate whether low-dose aspirin (<300 mg/d) can influence the onset of cognitive impairment or dementia in observational studies and improve cognitive test scores in randomized controlled trials (RCTs) in participants without dementia. DESIGN: Systematic review and meta-analysis. SETTING: Observational and interventional studies. PARTICIPANTS: Individuals with no dementia or cognitive impairment initially. MEASUREMENTS: Odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for the maximum number of covariates from each study, were used to summarize data on the incidence of dementia and cognitive impairment in observational studies. Standardized mean differences (SMDs) were used for cognitive test scores in RCTs. RESULTS: Of 2,341 potentially eligible articles, eight studies were included and provided data for 36,196 participants without dementia or cognitive impairment at baseline (mean age 66, 63% female). After adjusting for a median of three potential confounders over a median follow-up period of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies, N = 26,159; OR = 0.82, 95% CI = 0.55-1.22, P = .33, I 2 = 67%). In three RCTs (N = 10,037; median follow-up 5 years), the use of lowdose aspirin was not associated with significantly better global cognition (SMD=0.005, 95% CI=-0.04-0.05, P = .84, I 2 = 0%) in individuals without dementia. Adherence was lower in participants taking aspirin than in controls, and the incidence of adverse events was higher. CONCLUSION: This review found no evidence that lowdose aspirin buffers against cognitive decline or dementia or improves cognitive test scores in RCTs.
L ow-dose aspirin is often used for the prevention of cardiovascular disease (CVD) because of its antithrombotic properties. 1, 2 Aspirin has antiinflammatory properties, and inflammation plays an important role in several diseases. 3 Preclinical models suggest that aspirin may decrease neuroinflammation and oxidative stress in the central nervous system. 4, 5 These pleiotropic mechanisms of action of aspirin could aid in the prevention of cognitive decline or dementia.
Cardiovascular and cerebrovascular conditions are established risk factors for poor cognitive status and dementia. [6] [7] [8] The atherosclerotic process, which leads to plaque development and reduced oxygen availability to the brain, can explain the relationship between vascular disease and cognitive decline and dementia. 9 Dementia and cardio-and cerebrovascular diseases share several risk factors, particularly with diabetes mellitus. 10, 11 There has been growing interest in the use of drugs of a similar nature to aspirin, such as nonsteroidal antiinflammatory drugs (NSAIDs) for the prevention of dementia. 13 A growing body of research is suggesting a potential role for aspirin in the prevention of cognitive decline. Because dementia is irreversible, understanding whether low-dose aspirin is useful for the prevention of cognitive decline and improvement of cognitive function of people without dementia is important. A Cochrane systematic review including one randomized controlled trial (RCT) and 70 participants published in 2000 demonstrated no benefit of aspirin in preventing vascular dementia. 12 Since that time, further evidence has become available, and an updated comprehensive meta-analysis is required.
Given the aforementioned limitations in the literature, this study had the following aims: investigate whether lowdose aspirin use is associated with onset of dementia and decline in cognition in observational studies and whether low-dose aspirin use results in better cognitive test scores in RCTs of people without cognitive impairment or dementia. It was hypothesized that low-dose aspirin could have a favorable effect on cognition.
METHODS
This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta Analyses 14 and Meta-analysis Of Observational Studies in Epidemiology 15 statements and followed an a priori defined but unpublished protocol.
Data Sources and Literature Search Strategy
Two investigators (NV, MS) independently searched PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov without language restrictions from database inception to September 1, 2016 . Observational studies and RCTs investigating the effect of oral low-dose aspirin on the incidence of dementia or test scores assessing cognitive function in people without dementia or cognitive impairment at baseline were included. In PubMed, the following search strategy was used: (aspirin OR acetylsalicylic acid) AND (cognit*). Conference abstracts and reference lists of included articles were hand searched to identify any potential additional relevant articles. Any inconsistencies were resolved by consensus.
Study selection
Inclusion criteria for this meta-analysis were use of an RCT or longitudinal study design, use of low-dose aspirin (<300 mg/d 16 ), reporting data on dementia diagnosed through validated criteria, and reporting data of cognitive tests of global (e.g., Mini-Mental State Examination (MMSE) 17 ) or specific cognitive functions in adults without dementia or cognitive impairment.
Studies were excluded if they were not conducted in humans, used a nonplacebo control group (active controls in RCTs), or used dosages of aspirin with antiinflammatory aims (≥300 mg/d or for brief periods, <1 year) or if a standardized mean difference (SMD) or odds ratio (OR) could not be computed from the available data. If studies were encountered that did not provide sufficient data for the meta-analysis, the authors were contacted twice over a period of a month to request additional data.
Data extraction
Two investigators (NV, BS) extracted data from the articles in a standardized file, and a third independent investigator (MS) validated data extraction. Data were extracted about authors, year of publication, country, setting, demographic characteristics (sample size, mean age, percentage of women), follow-up duration, diagnostic criteria or tests used for diagnosis of dementia and cognitive impairment, and daily dose of aspirin. In longitudinal studies, information was extracted on number and type of covariates used in multivariate analyses. Data were extracted according to treatment group (low-dose aspirin and controls). If information was missing, the first or corresponding author of the original article was contacted at least two times in a month.
Outcomes
For longitudinal studies, the primary outcome was incidence of dementia or cognitive impairment during followup in the longitudinal studies. Dementia was ascertained through validated criteria, and cognitive impairment was ascertained according to predefined cut-offs of standardized test results for assessing cognitive status (e.g., MMSE score ≤24).
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For RCTs, changes between follow-up and baseline on tests assessing cognition (e.g., global cognition, verbal memory or fluency) were determined for participants without dementia or cognitive impairment at baseline in the group taking aspirin and in the control group (placebo, no intervention).
Assessment of Study Quality
Two authors (NV, BS) assessed the quality of studies using the Newcastle-Ottawa Scale (NOS) to evaluate longitudinal studies 18 and the Jadad scale 19 to assess RCTs.
Data Synthesis and Statistical Analysis
All analyses were performed using Comprehensive Metaanalysis 3 (Biostat, Englewood, NJ).
In the primary analysis, data regarding incidence of dementia and cognitive impairment in people using lowdose aspirin were compared with data of those receiving no treatment using the ORs with their 95% confidence intervals (CIs) adjusted for the maximum number of covariates available for each study. In the co-primary analysis, cognitive tests values of participants treated with low-dose aspirin were compared with those of controls (placebo or no intervention). Differences between the means of the treatment and control groups were calculated using change between follow-up and baseline data for each group, using SMDs with 95% CIs. In all analyses, a random-effects model was applied. 20 Heterogeneity across studies was assessed using the I 2 metric and Cochran Q chi-square statistics with a value of 50% or greater for the first and P < .05 indicating the presence of significant heterogeneity. 21 Publication bias was assessed by visually inspecting funnel plots and using the Begg-Mazumdar Kendall tau 22 and the Egger bias test. 23 The trim-and-fill method was used to account for publication bias, to adjust for any potential unpublished (imputed) studies. 24 For all analyses, P < .05 was considered statistically significant.
RESULTS

Search Results
The search yielded 2,341 nonduplicated articles. After excluding 2,325 articles based on title and abstract review, 16 articles were retrieved for full-text review, and eight studies (5 longitudinal, [25] [26] [27] [28] [29] 3 RCTs [30] [31] [32] ) were included ( Figure S1 ). The other eight studies were excluded because they included active controls (people taking another drug, n = 3); investigated acute effects of aspirin on cognition (dose >300 mg/d used for analgesic aims, n = 2); were reviews (n = 1) or protocols (n = 1); or reported data as linear regression estimates and thus were not metaanalyzable (n = 1).
Study and Participant Characteristics
Full descriptive details of the included studies are reported in Tables S1 and S2. This meta-analysis included 36,196 participants, of whom 8,484 (23.4%) received low-dose aspirin. Mean age was 66, and 63% of participants were female. All participants were community-dwelling and lived in Europe (6 studies) or the United States (2 studies).
Longitudinal Studies
The five longitudinal studies [25] [26] [27] [28] [29] included 26,159 community-dwelling participants with a mean age of 65.1, mainly women, for a median follow-up of 6 years. Three studies 25, 27, 28 investigated dementia as an outcome, and the other two 26,29 considered cognitive impairment (Table S1 ). The quality of the studies was sufficient (NOS mean 6, range: 6-7). 18 Of the 26,159 participants, 3,035 (11.6%) used lowdose aspirin. Participants using low-dose aspirin at baseline were significantly older (78.1 AE 5.3 vs 75.9 AE 6.4, P < .001) but no different emerged in terms of percentage of women (64% vs 69%, P = .15).
RCTs
The three RCTs [30] [31] [32] (two vs placebo 30, 32 and one 31 as addon therapy) included 10,037 participants with an average age of 66.8; 74% were female. Median follow-up was 5 years (range 3-9.6 years). One RCT 31 used MMSE score to determine cognitive status, and the other two 30, 32 used several tests (Table S2 ). The quality of the studies was good. 19 
Meta-analysis of Longitudinal Studies
After adjusting for a median of three potential confounders (range 0-7), the use of low-dose aspirin was not significantly associated onset of dementia or cognitive impairment (5 studies: OR = 0.82, 95% CI = 0.55-1.22, P = .33, I 2 =67%; Figure 1 ). Considering each study separately, only one study, 27 with the largest cohort available (n = 23,915 participants at baseline), reported a significantly lower risk of dementia at follow-up, taking into account four potential confounders (Table S2 ). Even though the three studies using dementia as the outcome 25, 27, 28 reported a lower risk (OR = 0.59 (95% CI = 0.33-1.05, P = .84, I 2 = 33%) than the other two which examined cognitive impairment 26, 29 (OR = 0.96, 95% CI = 0.62-1.51, P = .66, I 2 =59%), the interaction between aspirin use and outcome was not significant (P = .18). After removing one study 28 (a conference abstract), the results did not significantly change (OR = 0.72, 95% CI = 0.47-1.10, P = .14, I 2 =70%), with the studies assessing dementia reporting an OR equal to 0.59, (95% CI = 0.33-1.05, P = .07, I 2 = 33%).
Meta-analysis of Randomized Controlled Trials
The use of low-dose aspirin was not associated with better global cognitive test scores in the three RCTs including 10,037 participants [30] [31] [32] (SMD = 0.00, 95% CI = À0.04 to 0.05, P = .84, I 2 = 0%) ( Figure 2 ). Publication bias was unlikely.
Two studies 30, 32 reported information regarding verbal memory and executive function and fluency tests. Although no significant differences emerged in terms of verbal memory tests (SMD = À0.02, 95% CI = À0.06-0.03, P = .42, I
2 =0%), the use of low-dose aspirin was associated with slightly better executive function and fluency test results (SMD = 0.06, 95% CI = 0.02-0.11, P = .006, I 2 = 0%). This difference was estimated to correspond to 2.6 years younger age and a 20% lower risk of cognitive decline than with placebo 32 in a single study.
Adherence and Adverse Effects
In the three RCTs included, a lower percentage of participants using low-dose aspirin completed the RCTs (69.9%) than of controls (75.9%, chi-square test P = .005). Only two studies (one longitudinal, 25 one RCT 31 ) reported information regarding side effects. The prevalence of gastrointestinal adverse events was 10 times as high in people taking aspirin (15.2%) as in controls (1.4%, P < .001). Although the RCT 31 did not report the type of gastrointestinal side effects, the longitudinal study 25 reported a similar incidence of gastric ulcers between those taking and not taking aspirin (P = .17).
DISCUSSION
This meta-analysis found that the use of low-dose aspirin did not appear to be associated with lower incidence of dementia and cognitive impairment in observational studies. Across RCTs, no evidence was found of improvement in cognitive test scores in people who were free of dementia or cognitive impairment, although people using low-dose aspirin had a higher frequency of side effects (particularly gastrointestinal); this was limited to data from two studies.
Several hypotheses might explain these findings. First, the average age of the participants was 65. Previous research has suggested that the pathological changes typical of dementia happen 20 years before the clinical symptoms present 33 , so the use of low-dose aspirin at this age may be "too little, too late." Second, participants may have been taking low-dose aspirin for the secondary prevention of CVD or related conditions. Thus, preexisting comorbidities at baseline may have interfered with potential cognitive beneficial effects of low-dose aspirin and explain the null result. Finally, genetic factors could play a role in this lack of effect of low-dose aspirin. One study investigated whether the role of the apolipoprotein (APO)E gene altered the association between NSAID use and dementia risk and found lower risk of AD only in NSAID users with an APOE e4 allele. 34 Specific research is needed to clarify this potential hypothesis. Other factors may have accounted for the result across RCTs included in this meta-analysis, which also need to be considered. First, the number of people lost during follow-up could have influenced the results. Moreover, some of the cognitive tests, such as the MMSE, have important limitations, such as overestimation of cognitive impairments in persons aged 60 and older and in those with less education. 35 The current meta-analysis was designed to overcome this by using all of the tests available that assessed cognition and subcomponents such as executive function and fluency tests that aspirin use may improve, although the very small effect size detected in the latter suggests that the clinical significance of these findings is probably limited.
These findings are in partial agreement with two recent metaanalyses considering the effect of other NSAIDs on cognitive outcomes. Although participants in the longitudinal studies who took NSAIDs were 28% less likely to develop dementia, 13 the findings from the RCTs included in another meta-analysis did not support these observational findings. 36 Taken these findings together, it appears there is no consistent evidence that the use of NSAIDs may delay or prevent the onset of dementia or cognitive impairment over time, although future, adequately powered real-world investigations are required to better understand whether aspirin and other NSAIDs can delay or prevent dementia. Based on the current study findings, future RCTs should include more men and younger people. In this context, the ASPirin in Reducing Events in the Elderly Study, an ongoing trial including 19,000 healthy participants aged 65 and older could help better understand the possible role of aspirin in the prevention of dementia and mild cognitive impairment, 37 although particular attention should also be paid to adherence and any adverse events from such studies, and low-cost, lower-risk alternatives such as physical activity 38, 39 and nutrition interventions 40 should also be considered. Although few studies provided evidence on adherence and adverse events, the limited available evidence suggests that a higher incidence of adverse events could in part explain poorer adherence. Gastrointestinal side effects appear to be particularly troublesome. Some experts have suggested that aspirin may lead to an increase in gut permeability (leaky gut), which may lead to the translocation of bacterial products (e.g., lipopolysaccharide), which may increase microglial activation and therefore neuroinflammation. 5, 41, 42 Bearing in mind the possible limitations of the current study, these results suggest not only a lack of evidence that aspirin could protect against cognitive decline and dementia but that it may increase adverse gastrointestinal events.
The findings of this meta-analysis should be interpreted within its limitations. First, only a limited number of RCTs were identified. Although these studies were of high quality, with large sample sizes and long follow-up, other studies are needed to reach a definitive conclusion. Second, the observational studies did not use propensity score in their analyses, which is the best method for comparing a population taking a drug with another one that is not. 43 Moreover, the possibility of selection bias in longitudinal studies and the fact that a consistent percentage of people not taking aspirin took other NSAIDs might have created another important bias in the results. In addition, one study included the overwhelming majority of participants and thus could have had a large influence on the overall result. 26 Another limitation is the high heterogeneity observed in the longitudinal studies and that no metaregression analysis was possible because of the limited number of studies for each outcome. 44 Fourth, no study assessed the effect of low-dose aspirin in reducing dementia risk according to APOE e4 status, which could be a relevant factor in establishing a link between aspirin use and cognitive decline. It may be that only people with this mutation had a lower risk of dementia when taking aspirin, as shown by a large study analyzing the interaction between APOE e4 status and NSAIDs. 34 Fifth, conclusions on side effects of aspirin are based on only two studies. Finally, although potential confounding factors were accounted for when data were available by using adjusted effect estimates in the pooled analyses, it was not possible to consider other potentially important, unidentified confounders. For instance, people taking low-dose aspirin are more likely to be at risk of, or have a history of CVD than those not taking aspirin, and the indications for aspirin may vary across countries, and these may be influential factors. Thus, future research should attempt to consider, where possible, the effect of such factors on the relationship between aspirin and cognitive outcomes.
The strengths of this work include a comprehensive search of several databases and the inclusion of the largest possible number of participants; the long follow-up of each study; and that, to the best of our knowledge, this is the first systematic review and meta-analysis to consider this question.
In conclusion, this preliminary meta-analysis suggests that low-dose aspirin does not decrease the risk of cognitive decline (in terms of dementia or cognitive impairment) or improve cognitive test scores. Moreover, adherence to aspirin may be lower than to control conditions, and aspirin may cause adverse events. Future trials considering dementia onset as the outcome are needed to determine whether low-dose aspirin decreases cognitive decline and to test the possibility that low-dose aspirin has beneficial effects when taken over a longer period and at an earlier age than the observed population did.
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